Nexel Pharma received $3 million (approximately \u00a5473 million) from Centessa for achieving an early development milestone of the OX2R agonist ORX489 for neuropsychiatric disorders.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexel Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4565-20260305-01.pdf","jir_short_summary":"Nexel Pharma received $3 million (approximately \u00a5473 million) from Centessa for achieving an early development milestone of the OX2R agonist ORX489 for neuropsychiatric disorders.","jir_summary":"### Overview of Milestone Receipt\nNexel Pharma Inc. has received a new $3 million (approximately \u00a5473 million) milestone payment from its partner Centessa Pharmaceuticals Limited, following the achievement of an early development milestone for the orexin receptor 2 (OX2R) agonist ORX489 targeting neuropsychiatric disorders. This milestone will be recorded as revenue in the first quarter of the fiscal year ending December 2026.\n\n### Earnings Guidance and Future Outlook\nThe impact of this milestone on the consolidated earnings forecast for the fiscal year ending December 2026 has already been incorporated in the earnings guidance disclosed on February 13, 2026, with no revisions planned. Moving forward, the company will continue to advance numerous pipeline developments leveraging its proprietary drug discovery platform, NxWave\u2122.","jir_financial_highlights":"Milestone Amount Received: $3 million (approximately \u00a5473 million) (Unknown)\nRevenue Recognition Period: FY2026 Q1 (Unknown)\nImpact on Consolidated Earnings Guidance for FY2026: Factored In (Unknown)","jir_category":"","jir_hashtags":"#NexelPharmaInc, #business_update, #JapaneseStocks","jir_key_figures":"Milestone Amount Received: $3 million (approximately \u00a5473 million)\nRevenue Recognition Period: FY2026 Q1\nImpact on Consolidated Earnings Guidance: Factored In","jir_meta_title":"Nexel Pharma Announces Receipt of $3 Million Milestone Payment from Centessa","jir_meta_description":"Nexel Pharma received a $3 million (approx. \u00a5473 million) early development milestone payment for OX2R agonist targeting neuropsychiatric disorders from its partnership with Centessa. Revenue to be recognized in FY2026 Q1.","jir_og_title":"Nexel Pharma Receives $3 Million Milestone from Centessa","jir_og_description":"Nexel Pharma receives $3 million following milestone achievement in the development of a novel drug for neuropsychiatric disorders. Impact on earnings guidance is already factored in.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-33420","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n